Long-term Survival of Locally Advanced Stage III Non-small Cell Lung Cancer Patients Treated with Chemoradiotherapy and Perspectives for The Treatment with Immunotherapy

BACKGROUND: Standard treatment for patients with inoperable locally advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiotherapy (CCRT). Five-year overall survival rates range between 15 and 25%, while long term survival data are rarely reported. PATIENTS AND METHODS: A total of 102 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Vrankar, Martina, Stanic, Karmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137367/
https://www.ncbi.nlm.nih.gov/pubmed/30210037
http://dx.doi.org/10.2478/raon-2018-0009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137367/
https://www.ncbi.nlm.nih.gov/pubmed/30210037
http://dx.doi.org/10.2478/raon-2018-0009

Ejemplares similares